Pay in 4 interest-free payments of $5.92 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Nutr Cancer 1993
Resources such as Diabetes in Control articles and Healthcare.pro can further support informed discussions between clinicians and patients
Resmetirom (Rezdiffra TM ), a liver-directed thyroid hormone receptor- (THR-) agonist, received accelerated FDA approval in March 2024 as the first agent specifically indicated for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3), based on the MAESTRO-NASH trial demonstrating MASH resolution and fibrosis improvement
( Epub 20120919 )
US$ 26.32
US$ 29.68
US$ 25.04
US$ 26.31
US$ 28.96
US$ 22.17
US$ 28.98
US$ 23.65
